Antibacterial Drugs Market, By Drug Class (β-lactams, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols), By Distribution Channel (Hospital, Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, La

Antibacterial Drugs Market, By Drug Class (β-lactams, Quinolones, Macrolides, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols), By Distribution Channel (Hospital, Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Antibacterial drugs play a major role in advanced healthcare, as they are majorly used in treatment and prevention of infectious diseases. Antibacterial drugs act by destroying or inhibiting microbial growth. Antibacterial drugs are used in treatment of infection caused by various bacteria such as Escherichia coli, Klebsiella pneumonia, and others. Moreover, increasing incidences of infectious diseases such as tuberculosis, hepatitis B, leprosy, typhoid, malaria, HIV/AIDS and others is expected to drive the market growth. According to the World Health Organization (WHO) November 2018 factsheet, an estimated 219 million people were diagnosed by malaria in 2017, in 19 countries.
Restraints of the Global Antibacterial Drugs Market
Major factors hampering the growth of the antibacterial drugs market during the forecast period constitutes of increasing number of multi-drug resistant bacterial strains, and failure to advance robust therapies in the pipeline phases.
Key features of the study:
This report provides in-depth analysis of the global antibacterial drugs market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global antibacterial drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Shionogi Inc, Iterum Therapeutics plc, Kyorin Pharmaceutical Co., Ltd., Allecra Therapeutics GmbH, Wockhardt Ltd., Theravance Biopharma, Inc., R-Pharm Group, Entasis Therapeutics, Melinta Therapeutics, Micurx Pharmaceutical Inc., Debiopharm Group, Boston Pharmaceuticals Inc., TenNor Therapeutics, Sichuan Pharmaceutical Co., Ltd., NacuGen Therapeutics Inc., VenatoRx Pharmaceuticals, Inc., Spero Therapeutics, GlaxoSmithKline plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Forest Laboratories, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global Antibacterial Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Antibacterial Drugs Market, By Drug Class:
β-lactams
Quinolones
Macrolides
Tetracyclines
Aminoglycosides
Sulfonamides
Phenicols
Global Antibacterial Drugs Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Antibacterial Drugs Market, By Geography:
North America
By Drug Class
β-lactams
Quinolones
Macrolides
Tetracyclines
Aminoglycosides
Sulfonamides
Phenicols
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Class
β-lactams
Quinolones
Macrolides
Tetracyclines
Aminoglycosides
Sulfonamides
Phenicols
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Class
β-lactams
Quinolones
Macrolides
Tetracyclines
Aminoglycosides
Sulfonamides
Phenicols
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug Class
β-lactams
Quinolones
Macrolides
Tetracyclines
Aminoglycosides
Sulfonamides
Phenicols
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Drug Class
β-lactams
Quinolones
Macrolides
Tetracyclines
Aminoglycosides
Sulfonamides
Phenicols
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug Class
β-lactams
Quinolones
Macrolides
Tetracyclines
Aminoglycosides
Sulfonamides
Phenicols
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Shionogi Inc.*
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Iterum Therapeutics plc
Kyorin Pharmaceutical Co., Ltd.
Allecra Therapeutics GmbH
Wockhardt Ltd.
Theravance Biopharma, Inc.
R-Pharm Group
Entasis Therapeutics
Melinta Therapeutics
Micurx Pharmaceutical Inc.
Debiopharm Group
Boston Pharmaceuticals Inc.
TenNor Therapeutics
Sichuan Pharmaceutical Co., Ltd.
Other Major Players
“*” marked represents similar segmentation in other categories in the respective section.